Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (Nasdaq: SGHT) is an eyecare technology company that regularly issues news about its interventional glaucoma and dry eye businesses. As a manufacturer of ophthalmic medical devices, the company provides updates on its OMNI® and SION® glaucoma technologies and its TearCare® System for evaporative dry eye disease due to meibomian gland disease.
News for SGHT often includes quarterly and annual financial results, revenue guidance updates, and commentary on operating expenses and restructuring plans. The company uses press releases and Form 8-K filings to report results of operations, changes to loan agreements, and targeted cost-reduction initiatives designed to align its operating structure with long-term objectives.
Clinical and scientific developments are another recurring theme. Sight Sciences highlights peer-reviewed publications, systematic reviews, and meta-analyses evaluating the OMNI Surgical System in primary open-angle glaucoma, including standalone and cataract-combination procedures. It also reports on randomized controlled trials and guideline recognition related to the TearCare System in dry eye disease and meibomian gland disease.
Coverage decisions and reimbursement milestones frequently appear in the company’s announcements. Examples include jurisdiction-wide pricing for CPT® code 0563T, which describes the TearCare procedure, established by Medicare Administrative Contractors, and expanded coverage policies from commercial insurers for implant-free, minimally invasive glaucoma surgery procedures that include OMNI.
Corporate governance and leadership changes are also disclosed, such as executive promotions, board resignations, and new officer appointments. Investors following SGHT news can expect a mix of financial updates, clinical evidence summaries, reimbursement developments, and corporate actions related to its interventional eye care technologies.
Sight Sciences (Nasdaq: SGHT) provided preliminary, unaudited Q4 and full-year 2025 financial highlights for the period ended December 31, 2025. Q4 2025 revenue is expected to be $20.3M–$20.4M (≈+7% at midpoint). Full-year 2025 revenue is expected to be $77.3M–$77.4M (≈-3% at midpoint). Q4 Dry Eye revenue is ~$0.7M (+~130% YoY); full-year Dry Eye revenue is ~$1.6M vs $4.0M in 2024. Cash and cash equivalents were approximately $92M at Dec 31, 2025; cash used in 2025 totaled ~$28M. Results are preliminary and subject to audit with final results expected in March 2026.
Sight Sciences (NASDAQ: SGHT) reported three peer‑reviewed publications (Nov 1–Nov 11, 2025) showing the OMNI surgical system with TruSync technology lowers intraocular pressure (IOP) and medication use in cataract-combination and standalone glaucoma procedures, including analyses in African American patients.
Key results: a 24‑month prospective cohort (n=18) showed mean IOP 26.1 mmHg reduced by 9.7 mmHg at 12 months and 10.6 mmHg at 24 months, medications fell from 1.8 to 0.5 by 24 months, with two‑thirds medication‑free at Month 24. A ~13,000‑eye IRIS registry analysis found the highest ≥20% IOP reduction rate with OMNI among MIGS devices. A 220‑eye subgroup showed IOP reduction up to 3 years regardless of lens status or severity.
Sight Sciences (Nasdaq: SGHT) reported Q3 2025 results and raised full‑year guidance on Nov 6, 2025. Q3 revenue was $19.9M (‑1% YoY) with Surgical Glaucoma revenue of $19.7M (+6% YoY) and Dry Eye revenue of $0.2M (‑88% YoY). Gross profit was $17.2M and gross margin improved to 86%. Q3 adjusted operating expenses fell to $19.8M (‑17% YoY) and GAAP operating expenses were $25.1M, which included $2.8M of restructuring charges.
The company raised 2025 revenue guidance to $76.0M–$78.0M and cut adjusted operating expense guidance to $90M–$92M. Cash was $92.4M and long‑term debt $40.0M as of Sept 30, 2025.
Sight Sciences (Nasdaq: SGHT) announced the appointments of Alison (Ali) Bauerlein as Chief Operating Officer and James (Jim) Rodberg as Chief Financial Officer, effective November 5, 2025.
The company said the new COO role will support scaling reimbursed interventional dry eye and MIGS commercial efforts. Bauerlein joins the executive team after serving as Sight Sciences CFO since April 2023 and previously helped scale Inogen to over $350 million in annual sales. Rodberg was promoted from VP of Finance and corporate controller, has 20 years of finance and accounting experience and served as interim CFO in 2023.
The board also reported that Erica Rogers (six years) and Brenda Becker (three years) have stepped down from the board.
Sight Sciences (Nasdaq: SGHT) will present at two investor conferences in New York in November and December 2025. Management will present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 AM PT / 11:20 AM ET and at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 5:30 AM PT / 8:30 AM ET. Interested parties can access a live and archived webcast of each fireside chat via the company’s Investors website at https://investors.sightsciences.com/.
Sight Sciences (Nasdaq: SGHT) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025.
Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access a live and archived webcast on the company website at www.sightsciences.com under the Investors & News & Events section. The webcast replay will be available for at least 90 days after the event.
Sight Sciences (Nasdaq: SGHT) announced that two Medicare Administrative Contractors, Novitas Solutions and First Coast Service Options, established jurisdiction-wide pricing for CPT 0563T (TearCare procedure) effective for dates of service on or after January 1, 2025.
The two MACs cover an estimated 10.4 million covered lives, representing approximately 30% of Medicare fee-for-service enrollees in their jurisdictions. Claims will be payable based on individual medical necessity determinations and local fee schedules will be published on the MACs' websites.
The company also launched a Sight Access Portal to assist providers with benefit verifications and reimbursement, and said it will provide updated 2025 revenue and adjusted operating expenses guidance during its Q3 2025 earnings call.
Sight Sciences (NASDAQ:SGHT) announced the publication of a comprehensive meta-analysis in the European Journal of Ophthalmology demonstrating the long-term effectiveness of its OMNI® Surgical System for glaucoma treatment. The study, analyzing 29 publications covering 2,379 eyes, showed that 89% of patients achieved treatment success with IOP reduction ≥20% from baseline after 6-24 months.
Key findings revealed that 66-68% of patients remained medication-free after treatment, with significant IOP reductions maintained at 24 months. The system demonstrated cost-effectiveness compared to iStent inject®, with higher quality-adjusted life years (QALYs) of 8.95 over a lifetime horizon versus 8.93 for iStent inject.
Sight Sciences (NASDAQ:SGHT) announced that UnitedHealthcare (UHC) will include its OMNI® Surgical System in its expanded coverage policy for glaucoma surgical treatments, effective October 1, 2025. The coverage applies to UHC's commercial and individual exchange benefit plans, reaching approximately 30 million of UHC's over 50 million total covered lives.
The policy covers procedures including goniotomy, trabeculotomy, canaloplasty, and combined procedures for adults with mild to moderate open-angle glaucoma. The FDA-cleared OMNI Surgical System is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open angle glaucoma, and can be performed before, during, or after cataract surgery.
Sight Sciences (NASDAQ:SGHT) announced that its TearCare System has been included in the prestigious TFOS DEWS III report published in the American Journal of Ophthalmology. This recognition represents significant validation for TearCare's clinical efficacy in treating dry eye disease (DED) and meibomian gland disease (MGD).
The report highlights multiple clinical studies supporting TearCare's effectiveness, including the SAHARA trial, which demonstrated clinical superiority over Restasis in improving Tear Breakup Time and gland function, and the OLYMPIA trial, which showed significant improvement in DED symptoms, particularly in severe cases compared to LipiFlow.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
